It’s Official: Perrigo’s Entirely Consumer Health
"We are now a leading pure-play global consumer self-care company that has significant resources to invest,” says CEO Murray Kessler with Rx business sale closing.
You may also be interested in...
Jim Dillard, chief scientific officer for Perrigo since 2019, moves to head the North American business with research and development experience as well as a regulatory background from his work at the FDA.
HRA’s approval for pharmacy sales of a daily oral contraceptive the UK and its ongoing work on an NDA to propose making another progestin-only contraceptive ingredient available OTC in the US stand out as additions to Perrigo’s business with the most substantial revenue impacts.
OTC drug private label/store brand giant reports April-June overall net sales of $981m, up 3.4%. As its Americas business organic sales slipped 1.4% to $622m, international business sales grew 11.7% to $359m.